The short version of immunoassay fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-05. Anything still debated is marked as such rather than presented as settled.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
== A scientific home in Pittsburgh == In a few short years, the Dean of the School of Medicine, himself a professor of Biochemistry, invited Hofmann to become Chairman of the Department. From the moment he took the position of Chairman of Biochemistry, it became clear that although he would always be a son of Switzerland, the United States offered him career opportunities he could never hope for in a small country like Switzerland. The US was to become his permanent home. The burgeoning field of peptide chemistry became his scientific focus and, in his own words, he fell in love with a molecule that was known to stimulate the adrenal cortex to produce the very steroids that had so fascinated him in Reichstein's laboratory. That molecule, not yet isolated, was ACTH and the love affair was lifelong. Despite detours into other areas, he kept returning to ACTH. In the last years before his death, he was developing methods to isolate the ACTH receptor.
Peyronie's disease diagnosis is mostly clinical. Patient history and physical examination are crucial. The most prominent features are acquired penile curvature, palpable plaques, erectile dysfunction, and pain during erections. Penile ultrasonography is the imaging method of choice for plaque location, measurement, and confirmation of calcification. Doppler ultrasound can be utilized to assess vascular function, which is useful in the evaluation of associated erectile dysfunction. Imaging also helps to differentiate Peyronie's disease from congenital penile curvature, penile fracture, or neoplastic disease. MRI can be employed in severe ones, although it is generally not required.
== Work history == While researching at Case Western Reserve, Tippett moonlighted as an emergency room physician and instructor in Emergency and Outpatient Medicine. He spent much of his early clinical career (1989–1995) in Emergency Medicine in Ohio and California. He received his board certification in Internal Medicine in 1987. Between 1993 and 2000, he served on the board of the Computer Ethics Institute. He served as executive director of The Pacific Foundation for Science and Medicine from 1988 to 1992, an intersection of his clinical career with an emerging focus on technology, particularly cybersecurity, and the use and access protocols of the Internet. It was in his role as president and chairman of Certus International, a publisher and developer of PC anti-virus and security software, that Tippett applied his research insights as a biochemist to the concept of computer "viruses" to develop the anti-virus software, "Vaccine," which was later purchased by Symantec in 1992. His CEO role with Cybertrust led to a merger of Cybertrust by Verizon, and Tippett's role in the Verizon healthcare and security innovations divisions. Tippett served as chairman of the Alliance for Internet Security in 2000. He represented Verizon on the board of directors of The Open Identity Exchange (OIX) and the Information Card Foundation.
=== Ulcerative colitis === Infliximab targets TNF, thought to be more related to Th1 cytokines. Ulcerative colitis was thought to be a Th2 disease, and infliximab would be of limited use. However, patients with ulcerative colitis have begun to be treated with infliximab on the basis of two large clinical trials conducted in 2005 by Paul Rutgeerts and William Sandborn. The Acute ulcerative Colitis Treatment trials (ACT1 and ACT2) to evaluate the utility of infliximab in ulcerative colitis showed 44–45% of patients treated with infliximab for a year maintained a response to the medication, compared with 21% of patients who were treated with placebo medication. At two months, the response was 61–69% for patients treated with infliximab, and 31% for those treated with placebo.
===== Murder ===== 17 April 2015: Muhammad bin Kadar was hanged after spending five years and nine months on death row for the robbery and murder of an elderly housewife in 2005. He was sentenced to death by the High Court in 2009 and had his appeal dismissed by the Court of Appeal in 2011. He applied for re-sentencing when changes to the law took effect in 2013, but the Court of Appeal denied his application in 2014. He was eventually hanged on 17 April 2015 following the dismissal of his clemency plea. 16 July 2013: Fabian Adiu Edwin, a Malaysian who partnered with his childhood friend Ellary Puling to commit a series of six robberies in 2008, resulting in the death of one of the victims. While Ellary was sentenced to 19 years' imprisonment and 24 strokes of caning for robbery with hurt, Fabian was meanwhile convicted of murder and sentenced to death in 2011. The Court of Appeal dismissed his appeal against his sentence in 2012. After amendments to the law took effect in 2013, he applied for re-sentencing and was re-sentenced to life imprisonment and 24 strokes of the cane. 28 August 2013: Bijukumar Remadevi Nair Gopinathan, an Indian national who robbed and murdered a Filipino prostitute in 2010, was initially sentenced to death in 2012. He appealed to the Court of Appeal in 2012 but was still found guilty of murder. After changes to the law took effect in 2013, he applied for re-sentencing and was re-sentenced in 2013 to life imprisonment and 18 strokes of the cane.
Sources: en.wikipedia.org
Megakaryocyte and platelet production is regulated by thrombopoietin, a hormone produced in the kidneys and liver. Each megakaryocyte produces between 1,000 and 3,000 platelets during its lifetime. An average of 1011 platelets are produced daily in a healthy adult. Reserve platelets are stored in the spleen and are released when needed by splenic contraction induced by the sympathetic nervous system.
== Life == Vital Brazil Mineiro da Campanha was born on April 28, 1865, in the town of Campanha, in the state of Minas Gerais, Southeastern of the Empire of Brazil. His father gave him this curious name in homage to the country, the state and the city where he was born, as well as from the date, St. Vital’s Day. He graduated from the Rio de Janeiro School of Medicine in 1891, working as a technical assistant in the chair of Physiology in order to pay for his tuition and living expenses. After graduating, he began work in public health, initially as a sanitary inspector in São Paulo (1892–1895), where he acquired experience in the prevalent epidemic diseases of the time (smallpox, typhoid fever, yellow fever and cholera), and then as a private practitioner in the city of Botucatu, from 1895 to 1896.
He recalls that Boris Johnson struggled with scientific concepts, and that after a five-hour meeting with him, after the Prime Minister had returned from a "Battle of Britain memorial service and was distressed by seeing everyone separated and in masks", he "looked broken – his head in hands a lot." He quotes the PM saying "We are too shit to get our act together". He also recalls that Chief Medical Officer Chris Whitty had concerns about the "indirect harms" of lockdown. 21 November Four bodies are found by North Wales Police in the search for teenage boys missing for two days, after their car appeared to have left the road near Tremadog. A coroner's inquest later finds they drowned, after the vehicle overturned and became partially submerged in water. Chancellor Jeremy Hunt announces an increase in the National Living Wage to £11.44 from April 2024; with the increase also encompassing those aged 21 and 22 for the first time. 22 November Lady Justice Thirlwall formally opens the public inquiry into the activities of serial killer Lucy Letby. Jeremy Hunt delivers the November 2023 United Kingdom autumn statement. 23 November More than 50 firefighters tackle a major blaze at the Station Hill development in Reading. One person is lifted by crane from the roof of a building, and two people are treated in hospital for smoke inhalation. Office for National Statistics data suggests that in 2022, net migration—the difference between the number of people arriving in the UK and leaving the UK—was 745,000, something the UK government describes as too high.
=== Post-translational modifications === Most programs available for protein analysis are not written for proteins that have undergone post-translational modifications. Some programs will accept post-translational modifications to aid in protein identification but then ignore the modification during further protein analysis. It is important to account for these modifications since they can affect the protein's structure. In turn, computational analysis of post-translational modifications has gained the attention of the scientific community. The current post-translational modification programs are only predictive. Chemists, biologists and computer scientists are working together to create and introduce new pipelines that allow for analysis of post-translational modifications that have been experimentally identified for their effect on the protein's structure and function.
Sources: en.wikipedia.org
=== Phototaxis and UV response === As well as aligning with magnetic fields, "Ca. M. multicellularis" demonstrates clear photophobic and phototactic behaviours. When the organism is subjected to short pulses of ultraviolet (UV) light from a fluorescence microscope, it stops moving forward and immediately begins to swim backwards. This escape movement lasts for several seconds before it returns to its normal trajectory.
3,114km of high-pressure petroleum and gas pipelines An inland accumulation facility at Jameson Park, Gauteng (TM2), with a capacity of 180Ml A tank farm in Tarlton, Gauteng, for storage and distribution via rail and road, with a capacity of 29Ml A coastal terminal at Island View in Durban, for continuously supplying jet fuel to O.R. Tambo International Airport The Transnet pipeline network transports over 80% of refined fuel products for use in the inland market, and over 70% of the jet fuel used at O.R. Tambo International Airport. Approximately three-quarters of South Africa's fuel imports flow through Island View Precinct, which forms part of the Port of Durban. The Precinct serves as the country's main fuel storage and supply hub. Data for Transnet's pipeline fuel logistics is in the table below.
The most common wild yeasts found in the vineyard are from the genera Kloeckera, Candida and Pichia with the species Kloeckera apiculata being the most dominant species by far. Saccharomyces cerevisiae, itself, is actually quite rarely found in the vineyard or on the surface freshly harvested wine grapes unless the winery frequently reintroduced winery waste (such as lees and pomace) into the vineyard. Recent research has shown how climate change is starting to affect yeast behavior during fermentation. Due to rising temperatures, grapes are arriving at wineries with higher sugar levels. This puts more stress on yeast and increases the risk of stuck fermentations. Because of this, winemakers are starting to pay closer attention to what yeast they choose for fermentation more than ever before. Mixed fermentations, which use non-Saccharomyces yeasts alongside Saccharomyces cerevisiae, are also becoming increasingly popular to help enhance wine complexity and reduce volatile acidity. Unlike the "ambient" Saccharomyces wild yeast, these genera of wild yeasts have very low tolerance to both alcohol and sulfur dioxide. They are capable of starting a fermentation and often begin this process as early as the harvest bin when clusters of grapes get slightly crushed under their own weight. Some winemakers will try to "knock out" these yeasts with doses of sulfur dioxide, most often at the crusher before the grapes are pressed or allowed to macerate with skin contact.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.